Pfizer has received a licence extension for Xalatan 0.005% (latanoprost) permitting use of the eye drops in children with elevated intraocular pressure or glaucoma. Dosing is the same as for adults.
Latanoprost is the first prostaglandin analogue to complete safety and efficacy trials in the paediatric population and to be indicated for use in patients under 18 years old in the UK. No data are available for preterm infants (<36 weeks gestational age) and data are very limited in children under 1 year.
Further information: Pfizer